Company Overview and News

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 POS EX

2018-06-21 sec.gov
Document As filed with the Securities and Exchange Commission on June 21, 2018 Registration No. 333-213391
PBB

20
Legg Mason's (LM) CEO Pay Package for FY18 Jumps 8% Y/Y

2018-06-21 zacks
Legg Mason Inc.’s (LM - Free Report) chief executive officer (CEO) Joseph A. Sullivan’s total compensation, including a cash bonus, had been increased to $9.7 million in fiscal 2018. This represents a jump of 8% from the prior fiscal on higher incentives, according to a regulatory filing of Jun 20. In fiscal 2018, Sullivan’s pay package included salary of $500,000, unchanged from fiscal 2017, a cash bonus of $4 million (up from $3.
LAZ LMHA PBB LMHB LM AB PSEC

18
151 Monthly Paying Dividend SML Equities And 69 Funds For June

2018-06-21 seekingalpha
Here's your June 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains reports. Nano-Cap MoPays are not listed.
SCA CCAOF "NHF" CJ CBL WSR CRLFF AD ALARF CRIUF ORC MHIVF OXLCO OXLCN SCM ATGFF SOT.UN CJR.B ECC AMZA ECCZ AGNC AHOTF ECCY PHK SRRTF QYLD PSEC OXLC ECCB NCV CJREF SCQ ECCA SUNS GNL NCZ NHF GNL.PRA PBB SRT.UN

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 POS EX

2018-06-20 sec.gov
Document As filed with the Securities and Exchange Commission on June 20, 2018 Registration No. 333-213391
PBB

30
Upcoming Book Value Declines For This Higher Yielding BDC?

2018-06-20 seekingalpha
Two of PSEC's largest investments will likely have upcoming writedowns, especially given that company has a fiscal year-end June 30, requiring a full audit.
CLA MCQ TCAP KAP PNNT MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC PSEC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA

3
Prospect Capital Corporation: This 6.25% Baby Bond Has Begun Trading On The NYSE

2018-06-20 seekingalpha
Comparison with all other baby bonds that pay a fixed rate and have between 5 and 15 years to maturity.
PBY PBB PSEC

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 497

2018-06-19 sec.gov
Document Filed Pursuant to Rule 497 File No. 333-213391
PBB

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 497AD

2018-06-18 sec.gov
Document Filed Pursuant to Rule 497(a) File No. 333-213391
PBB

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 497

2018-06-18 sec.gov
Document Prospect Capital Corporation
PBB

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 497

2018-06-18 sec.gov
Document The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus supplement and prospectus are not offers to sell these securities and are not soliciting an o
PBB

16
Prospect Capital Announces Pricing of $70 Million of 5.875% Senior Notes due 2023

2018-06-18 globenewswire
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) (“Prospect”, “our”, or “we”) announced today the pricing of $70 million in aggregate principal amount of senior unsecured 5.875% Senior Notes due 2023 (the “Notes”).
PBB BR PSEC

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 497AD

2018-06-18 sec.gov
Document Filed Pursuant to Rule 497(a) File No. 333-213391
PBB

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 497AD

2018-06-18 sec.gov
Document Filed Pursuant to Rule 497(a) File No. 333-213391
PBB

0
Prospect Capital Receives BBB Investment Grade Corporate Rating From Egan-Jones Ratings Company, Representing Prospect's Third Investment Grade Rating

2018-06-18 globenewswire
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) (“Prospect”, “our”, or “we”) today announced it has been assigned an investment grade credit rating of BBB from Egan-Jones Ratings Company (“Egan-Jones”).
PBB PSEC

0
PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 497

2018-06-18 sec.gov
Document Filed Pursuant to Rule 497 File No. 333-213391
PBB

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to PBB / Prospect Capital Corp. 6.25% Bond due 2024-06-15 on message board site Silicon Investor.

American Pacific Bank AMPBB
CUSIP: 74348T300